NCT01062451

An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence

An ACE Inhibitor or an Angiotensin Receptor Blocker as a Treatment for Methamphetamine Dependence

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Baylor College of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The primary objective is to determine the dose dependent effects of treatment with perindopril on methamphetamine (MA)-induced craving and on the reinforcing effects of MA indexed by MA self-administration. We will also determine the effects of treatment with candesartan on MA-induced craving and on the reinforcing effects of MA indexed by MA self-administration.

Detailed description

Our preliminary data indicate that the ACE inhibitor perindopril can attenuate MA-induced drug craving, suggesting that perindopril should be evaluated as a treatment for MA dependence. Candesartan works similarly to perindopril but should lack the U-shaped dose response. Like perindopril, candesartan is used for hypertension. Whereas perindopril reduces the synthesis of angiotensin II, candesartan blocks angiotensin II receptors.

Conditions

• Methamphetamine Dependence
• Methamphetamine Abuse
• Substance Abuse

Interventions

Type	Name	Description
DRUG	Perindopril	8 mg taken orally from days 0 through 7.
DRUG	Placebo	Placebo treatment daily.
DRUG	Candesartan	16 mg taken orally from days 0 through 7.

Timeline

• Start date: 2009-05-01
• Primary completion: 2013-11-20
• Completion: 2013-11-20
• First posted: 2010-02-04
• Last updated: 2022-04-26

Locations

1 site across 1 country: United States